

# ANUH PHARMA LTD.

**Registered Office :** 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI** - 400 018. **INDIA.**  
**Tel. :** +91-22-6622 7575 • **Fax :** +91-22-6622 7600 / 7500  
**E-Mail :** anuh@sk1932.com • **CIN:** L24230MH1960PLC011586

Date: 10<sup>th</sup> February, 2023

To,  
The Manager (Listing)  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai - 400 001

**Ref: Scrip Code No. 506260**

**Sub: Outcome of Board Meeting dated 10<sup>th</sup> February, 2023.**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Board of Directors of the Company (the "Board") at its Meeting held today i.e. **Friday, 10<sup>th</sup> February, 2023**, inter-alia considered and approved the following agenda Items:

1. The **Un-Audited Financial Results** along with Limited Review Report thereon for the quarter ended 31<sup>st</sup> December, 2022.
2. The Board has approved the **Resignation of Mr. Lalitkumar P Shah** from the post of Director of Anuh Pharma Limited with immediate effect.

The Meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 4:15 p.m.

Thanking you,  
Yours faithfully,

For **Anuh Pharma Ltd.**



**Hemant Auti**  
**Company Secretary & Compliance Officer**

**Encl:** 1. Un-audited Financial Results along with Limited Review Report.

2. Resignation Letter of Mr. Lalitkumar P Shah along with Annexure I.



**We Serve Since 1932**

**Factory :** E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. **Tel.:** +91-7410055574 / 75

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**TO THE BOARD OF DIRECTORS  
Anuh Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter ended 31<sup>st</sup> December, 2022 and year to date results for the period from 1<sup>st</sup> April, 2022 to 31<sup>st</sup> December, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015; including the manner in which it is to be disclosed, or that it contains any material misstatement.



**PLACE: Mumbai**  
**DATE: 10<sup>th</sup> February, 2023**

**For JAYANTILAL THAKKAR & CO.**  
**CHARTERED ACCOUNTANTS**  
**(FIRM REG. NO. 104133W)**

*Dilip J. Thakkar*

**DILIP J. THAKKAR**  
**PARTNER**  
**MEMBERSHIP NO. 005369**  
**UDIN: 23005369BGVXOH2347**

**ANUH PHARMA LTD.**  
CIN: L24230MH1960PLC011586


Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018  
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2022

(Rs. in Lakhs)

| Sr. No. | Particulars  | 3 months ended 31/12/2022 | 3 months ended 30/09/2022 | 3 months ended 31/12/2021 | 9 months ended 31/12/2022 | 9 months ended 31/12/2021 | 12 months ended 31/03/2022 |
|---------|--|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|----------------------------|
|         |  | Unaudited                 | Unaudited                 | Unaudited                 | Unaudited                 | Unaudited                 | Audited                    |
| (1)     | (2)  | (3)                       | (4)                       | (5)                       | (6)                       | (7)                       | (8)                        |
| I.      | Revenue from operations  | 13,872.99                 | 11,506.98                 | 13,166.43                 | 37,017.62                 | 35,767.64                 | 48,664.62                  |
| II.     | Other income   | 211.26                    | 200.97                    | 33.86                     | 507.73                    | 416.82                    | 519.71                     |
| III.    | <b>Total Income (I + II)</b>   | <b>14,084.25</b>          | <b>11,707.95</b>          | <b>13,200.29</b>          | <b>37,525.35</b>          | <b>36,184.46</b>          | <b>49,184.33</b>           |
| IV.     | Expenses:  |                           |                           |                           |                           |                           |                            |
|         | Cost of materials consumed   | 9,134.66                  | 7,574.24                  | 8,862.90                  | 25,446.95                 | 25,708.26                 | 35,171.18                  |
|         | Purchases of Stock-in-Trade  | 132.06                    | 159.26                    | 2,017.57                  | 993.29                    | 2,427.15                  | 3,082.53                   |
|         | Changes in inventories of finished goods, work-in-progress and Stock-in-Trade  | 1,446.64                  | 662.64                    | (564.87)                  | 1,501.70                  | (103.89)                  | (485.63)                   |
|         | Employee benefits expense  | 432.44                    | 421.80                    | 375.38                    | 1,280.16                  | 1,108.03                  | 1,510.05                   |
|         | Finance costs  | 2.91                      | 10.61                     | 57.71                     | 19.50                     | 113.81                    | 96.09                      |
|         | Depreciation and amortization expense  | 243.34                    | 244.19                    | 299.21                    | 729.28                    | 895.31                    | 1,195.97                   |
|         | Other expenses   | 1,484.30                  | 1,346.30                  | 1,261.93                  | 4,091.43                  | 3,330.59                  | 4,701.94                   |
|         | <b>Total expenses (IV)</b>   | <b>12,876.35</b>          | <b>10,419.04</b>          | <b>12,309.83</b>          | <b>34,062.31</b>          | <b>33,479.26</b>          | <b>45,272.13</b>           |
| V.      | <b>Profit / (Loss) before exceptional and items and tax (III - IV)</b>   | <b>1,207.90</b>           | <b>1,288.91</b>           | <b>890.46</b>             | <b>3,463.04</b>           | <b>2,705.20</b>           | <b>3,912.20</b>            |
| VI.     | Exceptional items  | -                         | -                         | -                         | -                         | -                         | -                          |
| VII.    | <b>Profit / (Loss) before tax (V - VI)</b>   | <b>1,207.90</b>           | <b>1,288.91</b>           | <b>890.46</b>             | <b>3,463.04</b>           | <b>2,705.20</b>           | <b>3,912.20</b>            |
| VIII.   | Tax expenses:  |                           |                           |                           |                           |                           |                            |
|         | (1) Current tax  | 276.00                    | 309.00                    | 257.00                    | 831.00                    | 698.00                    | 1,058.00                   |
|         | (2) Deferred tax   | 1.29                      | (11.61)                   | (8.87)                    | (23.62)                   | (53.90)                   | (99.46)                    |
|         | (3) Income tax of earlier years  | -                         | -                         | (102.47)                  | -                         | (102.47)                  | (102.47)                   |
|         | <b>Total Tax expenses (VIII)</b>   | <b>277.29</b>             | <b>297.39</b>             | <b>145.66</b>             | <b>807.38</b>             | <b>541.63</b>             | <b>856.07</b>              |
| IX.     | <b>Profit/(Loss) after Tax (VII-VIII)</b>  | <b>930.61</b>             | <b>991.52</b>             | <b>744.80</b>             | <b>2,655.66</b>           | <b>2,163.57</b>           | <b>3,056.13</b>            |
| X.      | Other Comprehensive Income (net of Tax)  |                           |                           |                           |                           |                           |                            |
|         | (i) Items that will not be reclassified to profit or loss  | 0.02                      | (9.02)                    | 7.53                      | (7.30)                    | 8.42                      | 8.48                       |
|         | (ii) Items that will be reclassified to profit or loss   | -                         | -                         | -                         | -                         | -                         | -                          |
|         | <b>Total Other Comprehensive Income (net of Tax) (X)</b>   | <b>0.02</b>               | <b>(9.02)</b>             | <b>7.53</b>               | <b>(7.30)</b>             | <b>8.42</b>               | <b>8.48</b>                |
| XI.     | <b>Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b> | <b>930.63</b>             | <b>982.50</b>             | <b>752.33</b>             | <b>2,648.36</b>           | <b>2,171.99</b>           | <b>3,064.61</b>            |
|         | Paid up Equity Share Capital (Face value ₹ 5/- each)   | 2,505.60                  | 2,505.60                  | 2,505.60                  | 2,505.60                  | 2,505.60                  | 2,505.60                   |
|         | Other Equity (excluding revaluation reserves)  |                           |                           |                           |                           |                           | 18,871.68                  |
| XII.    | Earnings per equity share (For respective periods) (In Rs.)  |                           |                           |                           |                           |                           |                            |
|         | (1) Basic  | 1.86                      | 1.98                      | 1.49                      | 5.30                      | 4.32                      | 6.10                       |
|         | (2) Diluted  | 1.86                      | 1.98                      | 1.49                      | 5.30                      | 4.32                      | 6.10                       |

See accompanying notes to the financial results



Notes:-

1. The results of the quarter and nine months ended December 31, 2022 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 10, 2023. The statutory auditors of the Company carried out a "Limited Review" of the financial results for quarter and nine months ended December 31, 2022.

2. Other Financial indicators

(Rs. in Lakhs)

| Particulars   | 3 months ended<br>31/12/2022 | 3 months ended<br>30/09/2022 | 3 months ended<br>31/12/2021 | 9 months ended<br>31/12/2022 | 9 months ended<br>31/12/2021 | 12 months ended<br>31/03/2022 |
|---|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|-------------------------------|
| EBITDA  | 1,454.15                     | 1,543.71                     | 1,247.38                     | 4,211.82                     | 3,714.33                     | 5,204.26                      |
| % of EBITDA Margin  | 10.48                        | 13.42                        | 9.47                         | 11.38                        | 10.38                        | 10.69                         |
| EBITDA<br>(Adjusted to Forex (gain) / loss and Mark to Market<br>(gain) / loss on Investment in Mutual funds) | 1,406.69                     | 1,451.15                     | 1,353.67                     | 4,135.64                     | 3,721.78                     | 5,241.59                      |
| % of Adjusted EBITDA Margin   | 10.14                        | 12.61                        | 10.28                        | 11.17                        | 10.41                        | 10.77                         |

3. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

4. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.



For Anuh Pharma Ltd.

Ritesh Shah  
Joint Managing Director  
(DIN: 02496729)

Place : Mumbai

Date : 10th February, 2023

Date: 10<sup>th</sup> February, 2023

Lalitikumar Popatlal Shah

B-2/2, Amalfi, 27B,

L.D. Ruparel Marg, Malabar Hill, Mumbai – 400006

To,

The Chairman

Anuh Pharma Limited

**Subject: Resignation from the post of Director of Anuh Pharma Limited.**

Respected Sir,

I have been offering my duties as a Director of Anuh Pharma Limited since more than three decades.

I have the pleasure of seeing the Company substantially from the Inception.

Due to my ill health & age of 88 years, I would like to resign as a Director with immediate effect.

I acknowledge the co-operation from all the members of the Board of Directors and my best wishes for the future of our company.

Yours faithfully,



Lalitikumar P. Shah

(DIN: 00396345)



# ANUH PHARMA LTD.

**Registered Office :** 3-A, Shivsagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, **MUMBAI** - 400 018. **INDIA.**  
**Tel. :** +91-22-6622 7575 • **Fax :** +91-22-6622 7600 / 7500  
**E-Mail :** anuh@sk1932.com • **CIN:** L24230MH1960PLC011586

## Annexure I

| Sr. No | Disclosure requirement   | Details                               |
|--------|--|---------------------------------------|
| 1      | Name   | Mr. Lalitkumar P Shah                 |
| 2      | DIN  | 00396345                              |
| 3      | Date of Resignation  | February 10 <sup>th</sup> , 2023      |
| 4      | Brief Profile  | Not Applicable                        |
| 5      | Disclosure of relationship between Directors (in case appointment of a Director) | Not Applicable                        |
| 6      | Other Directorship and category  | Not Applicable                        |
| 7      | Membership of Committee  | Not Applicable                        |
| 8      | Reason for Change viz. appointment, resignation, removal, death or otherwise     | Due to ill health and age of 88 years |

For **Anuh Pharma Ltd.**



**Hemant Auti**  
**Company Secretary & Compliance Officer**

